Valuation: Cocrystal Pharma, Inc.

Market Cap 19.65M 17.47M 16.19M 14.73M 27.79M 1.86B 28.24M 195M 76.29M 973M 73.74M 72.17M 3.1B P/E 2026 *
-1.41x
P/E 2027 * -2.15x
Enterprise Value 19.65M 17.47M 16.19M 14.73M 27.79M 1.86B 28.24M 195M 76.29M 973M 73.74M 72.17M 3.1B EV / Sales 2026 *
0.18x
EV / Sales 2027 * -
Free-Float
34.29%
Yield 2026 *
-
Yield 2027 * -
1 day-0.97%
1 week-4.67%
Current month-11.30%
1 month-10.53%
3 months+7.37%
6 months-32.45%
Current year+4.19%
1 week 1.01
Extreme 1.01
1.11
1 month 1.01
Extreme 1.01
1.28
Current year 0.76
Extreme 0.76
2.03
1 year 0.76
Extreme 0.76
2.03
3 years 0.76
Extreme 0.76
3.26
5 years 0.76
Extreme 0.76
12
10 years 0.76
Extreme 0.76
180
Manager TitleAgeSince
Chief Executive Officer 65 2026-06-02
Chief Executive Officer 59 2021-05-26
Chief Executive Officer 66 2021-05-26
Director TitleAgeSince
Director/Board Member 89 2014-01-01
Chairman 79 2021-05-26
Director/Board Member 65 2014-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
8/5/26 Buy

Director

10,000 0.0725%
8/3/26 Buy

Director

75,000 0.5440%
6/3/26 Free

Chief Executive Officer

235,000 1.7044%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-4.67%-4.67%-43.96% 19.65M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -1.59%-0.69%+40.50%+80.49% 37.24B
Weighted average by Cap. -2.20%-0.50%+44.24%+96.53%

Financials

2026 *2027 *
Net sales 110M 97.78M 90.63M 82.46M 156M 10.44B 158M 1.09B 427M 5.45B 413M 404M 17.37B -
Net income -11.66M -10.36M -9.6M -8.74M -16.49M -1.11B -16.75M -115M -45.26M -577M -43.75M -42.82M -1.84B -10.75M -9.56M -8.86M -8.06M -15.21M -1.02B -15.45M -106M -41.74M -532M -40.34M -39.49M -1.7B
Net Debt - -
Projected Income Statement - Annual - Cocrystal Pharma, Inc.
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
26-10-16 US$1.020 -0.97% 22,975
26-10-15 US$1.030 -0.96% 45,597
26-10-14 US$1.040 -3.70% 47,810
26-10-13 US$1.080 +1.89% 86,702
26-10-12 US$1.060 -0.93% 8,967
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cocrystal Pharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.020USD
Average target price
8.000USD
Spread / Average Target
+684.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cocrystal Pharma, Inc.
  1. Stock Market
  2. Stocks
  3. COCP Stock